Cambodia

Population 2017: 16 million

Tuberculosis profile

**Estimates of TB burden**, 2017

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>3.1 (2.4–4.3)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.41 (0.27–0.57)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>52 (36–72)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.3 (0.89–1.8)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>1.2 (0.52–2.1)</td>
</tr>
</tbody>
</table>

**Estimated TB incidence by age and sex (thousands)**, 2017

<table>
<thead>
<tr>
<th></th>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>3.1 (1.4–4.8)</td>
<td>19 (8.6–29)</td>
<td>22 (11–32)</td>
</tr>
<tr>
<td>Males</td>
<td>3.4 (1.8–5.3)</td>
<td>27 (12–41)</td>
<td>30 (16–45)</td>
</tr>
<tr>
<td>Total</td>
<td>6.5 (4–9.1)</td>
<td>46 (28–63)</td>
<td>52 (36–72)</td>
</tr>
</tbody>
</table>

**TB case notifications**, 2017

- Total cases notified: 34,467
- Total new and relapse: 34,238
- % tested with rapid diagnostics at time of diagnosis: 87%
- % with known HIV status: 66%
- % bacteriologically confirmed among pulmonary: 54%

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2017: 66% (48–96)
- TB/HIV care in new and relapse TB patients, 2017: 748 (3%)
- % on antiretroviral therapy: 93%

**Drug-resistant TB care, 2017**

- New cases: 560 (290–840)
- Previously treated cases: 136, XDR-TB: 1
- Patients started on treatment ****: 143, XDR-TB: 1

**Treatment success rate and cohort size**

- New and relapse cases registered in 2016: 94% (32,478)
- Previously treated cases, excluding relapse, registered in 2016: 92% (38)
- MDR/RR-TB cases started on second-line treatment in 2015: 71% (75)

**TB preventive treatment**, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 21%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 44% (40–48)

**TB financing**, 2018

- National TB budget (US$ millions): 37
- Funding source: 12% domestic, 24% international, 64% unfunded

---

*Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-03-18

Data: www.who.int/tb/data